Mingyu Liu

TL;DR: Clinical evidence correlating improved glycemic control with better outcomes in patients with COVID-19 and pre-existing T2D is provided, associated with markedly lower mortality compared to individuals with poorly controlled BG during hospitalization.

TL;DR: Among hospitalized patients with COVID-19 and coexisting hypertension, inpatient use of ACEI/ARB was associated with lower risk of all-cause mortality compared with ACEi/ARB nonusers, and it is unlikely that in-hospital use ofACEI/ARB wasassociated with an increased mortality risk.

TL;DR: A retrospective study on 13,981 patients with COVID-19 in Hubei Province, China found that the risk for 28-day all-cause mortality was 5.2% and 9.4% in the matched statin and non-statin groups, respectively, with a hazard ratio 0.58, implying the potential benefits of statin therapy in hospitalized subjects with CO VID-19.

TL;DR: In this paper, the authors developed a sensitive and clinically applicable risk assessment tool identifying coronavirus disease 2019 (COVID-19) patients with a high risk of mortality at hospital admission.

TL;DR: The clinical and genetic features of an infant diagnosed with NEDSGA caused by a GRIA4 variant, who presented with severe developmental delay, limb hypertonia, generalized seizure, retinal hypoplasia, and chorioretinal hyperpigmentation are presented.